Literature DB >> 21277315

Synaptic plasticity and addiction: learning mechanisms gone awry.

Manuel Mameli1, Christian Lüscher.   

Abstract

Experience-dependent changes in synaptic strength, or synaptic plasticity, may underlie many learning processes. In the reward circuit for example, synaptic plasticity may serve as a cellular substrate for goal-directed behaviors. Addictive drugs, through a surge of dopamine released from neurons of the ventral tegmental area, induce widespread synaptic adaptations within this neuronal circuit. Such drug-evoked synaptic plasticity may constitute an early cellular mechanism eventually causing compulsive drug-seeking behavior in some drug users. In the present review we will discuss how different classes of addictive drugs cause an increase of dopamine release and describe their effects on synapses within the mesolimbic dopamine system. We will emphasize the early synaptic changes in the ventral tegmental area common to all additive drugs and go on to show how these adaptations may reorganize neuronal circuits, eventually leading to behaviors that define addiction.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277315     DOI: 10.1016/j.neuropharm.2011.01.036

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  40 in total

1.  NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD).

Authors:  Christian Lüscher; Robert C Malenka
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-06-01       Impact factor: 10.005

2.  Effect of amphetamine place conditioning on excitatory synaptic events in the basolateral amygdala ex vivo.

Authors:  A Hetzel; G E Meredith; D J Rademacher; J A Rosenkranz
Journal:  Neuroscience       Date:  2012-01-18       Impact factor: 3.590

3.  Resting state synchrony in long-term abstinent alcoholics: Effects of a current major depressive disorder diagnosis.

Authors:  George Fein; Jazmin Camchong; Valerie A Cardenas; Andy Stenger
Journal:  Alcohol       Date:  2016-11-23       Impact factor: 2.405

Review 4.  From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.

Authors:  Jane B Acri; Alan J Cross; Phil Skolnick
Journal:  Psychopharmacology (Berl)       Date:  2016-12-20       Impact factor: 4.530

5.  Locomotor sensitization to ethanol impairs NMDA receptor-dependent synaptic plasticity in the nucleus accumbens and increases ethanol self-administration.

Authors:  Karina Possa Abrahao; Olusegun J Ariwodola; Tracy R Butler; Andrew R Rau; Mary Jane Skelly; Eugenia Carter; Nancy P Alexander; Brian A McCool; Maria Lucia O Souza-Formigoni; Jeffrey L Weiner
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

6.  Natural and drug rewards act on common neural plasticity mechanisms with ΔFosB as a key mediator.

Authors:  Kyle K Pitchers; Vincent Vialou; Eric J Nestler; Steven R Laviolette; Michael N Lehman; Lique M Coolen
Journal:  J Neurosci       Date:  2013-02-20       Impact factor: 6.167

Review 7.  Metaplasticity at the addicted tetrapartite synapse: A common denominator of drug induced adaptations and potential treatment target for addiction.

Authors:  Daniela Neuhofer; Peter Kalivas
Journal:  Neurobiol Learn Mem       Date:  2018-02-09       Impact factor: 2.877

Review 8.  mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?

Authors:  Olga A Dravolina; Edwin Zvartau; Wojciech Danysz; Anton Y Bespalov
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

Review 9.  Dopamine Prediction Errors in Reward Learning and Addiction: From Theory to Neural Circuitry.

Authors:  Ronald Keiflin; Patricia H Janak
Journal:  Neuron       Date:  2015-10-21       Impact factor: 17.173

Review 10.  Epigenetics and psychostimulant addiction.

Authors:  Heath D Schmidt; Jacqueline F McGinty; Anne E West; Ghazaleh Sadri-Vakili
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.